Boehringer Ingelheim Venture Fund co-led a series A round set to drive clinical work on UC Berkeley-founded Actym Therapeutics' immunotherapy pipeline.
Actym Therapeutics, a US-based immuno-oncology drug developer allied to University of California, Berkeley, closed a $34m series A round on Monday co-led by pharmaceutical firm Boehringer Ingelheim’s Venture Fund (BIVF).
Healthcare-focused venture capital firm Panacea Venture co-led the round, which included Illumina Ventures, the investment arm of genomic technology provider Illumina, as well as Korea Investment Partners and JLo Ventures.
Founded in 2017, Actym is working on intravenous cancer immunotherapies that target immune cells in the microenvironment of…
